Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 707-713

  Huang, C N ^a   Huang, S P ^a,b,c   Pao, J B ^d   Chang, T Y ^e   Lan, Y H ^e   Lu, T L ^e   Lee, H Z ^e   Juang, S H ^e   Wu, P P ^e   Pu, Y S ^f   Hsieh, C J ^g,h   Bao, B Y ^e,i  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g ORIENTAL INSTITUTE OF TECHNOLOGY   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Androgen ; Androgen deprivation therapy; Nucleotide polymorphism; Prostate cancer; Responsive element; Single

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; GONADORELIN AGONIST;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARRDC3 GENE; ARTICLE; BINDING SITE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; FBXO32 GENE; FLT1 GENE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HORMONE RESPONSIVE ELEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM; SKAP1 GENE;

AGED; ANDROGEN ANTAGONISTS; ARRESTINS; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; PHOSPHOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84863250418     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr264     Document Type: Article

References (40)

1. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
2. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1665-1671.
3. Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 2007; 82: 243-249.
4. Choueiri TK, Xie W, D'Amico AV et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormonesensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009; 115: 981-987.
5. Hussain M, Tangen CM, Higano C et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 3984-3990.
6. Stewart AJ, Scher HI, Chen MH et al. Prostate-specific antigen nadir and cancerspecific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005; 23: 6556-6560.
7. Bao BY, Pao JB, Huang CN et al. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res 2011; 17: 928-936.
8. Huang SP, Chou YH, Wayne Chang WS et al. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett 2004; 207: 69-77.
9. Huang SP, Huang CY, Wang JS et al. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res 2007; 13: 6632-6638.
10. Huang SP, Huang CY, Wu WJ et al. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer 2006; 119: 1902-1907.
11. Huang SP, Huang LC, Ting WC et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009; 18: 3068-3074.
12. Huang SP, Ting WC, Chen LM et al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 2010; 17: 312-322.
13. Huang SP, WuWJ, ChangWS et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2217-2224.
14. Kwak C, Jeong SJ, Park MS et al. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002; 168: 995-1000.
15. Ross RW, Oh WK, Xie W et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008; 26: 842-847.
16. Zeitlinger J, Simon I, Harbison CT et al. Program-specific distribution of a transcription factor dependent on partner transcription factor and MAPK signaling. Cell 2003; 113: 395-404.
17. Ferretti V, Poitras C, Bergeron D et al. PReMod: a database of genome-wide mammalian cis-regulatory module predictions. Nucleic Acids Res 2007; 35: D122-D126.
18. Bulyk ML. Computational prediction of transcription-factor binding site locations. Genome Biol 2003; 5: 201.
19. Roche PJ, Hoare SA, Parker MG. A consensus DNA-binding site for the androgen receptor. Mol Endocrinol 1992; 6: 2229-2235.
20. Karolchik D, Hinrichs AS, Furey TS et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res 2004; 32: D493-D496.
21. Thorisson GA, Smith AV, Krishnan L et al. The International HapMap Project Web site. Genome Res 2005; 15: 1592-1593.
22. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003; 100: 9440-9445.
23. Benjamini Y, Yekutieli D. Quantitative trait Loci analysis using the false discovery rate. Genetics 2005; 171: 783-790.
24. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991; 67: 3057-3064.
25. van der Kwast TH, Schalken J, Ruizeveld de Winter JA et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991; 48: 189-193.
26. Chodak GW, Kranc DM, Puy LA et al. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 1992; 147: 798-803.
27. Alvarez CE. On the origins of arrestin and rhodopsin. BMC Evol Biol 2008; 8: 222.
28. Draheim KM, Chen HB, Tao Q et al. ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta4. Oncogene 2010; 29: 5032-5047.
29. MacLean HE, Chiu WS, Notini AJ et al. Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. FASEB J 2008; 22: 2676-2689.
30. Pallares J, Rojo F, Iriarte J et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 2006; 21: 857-865.
31. Sieveking DP, Lim P, Chow RW et al. A sex-specific role for androgens in angiogenesis. J Exp Med 2010; 207: 345-352.
32. Dror Michaelson M, Regan MM, Oh WK et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20: 913-920.
33. Ryan CJ, Stadler WM, Roth B et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 2007; 25: 445-451.
34. Fang L, Seki A, Fang G. SKAP associates with kinetochores and promotes the metaphase-to-anaphase transition. Cell Cycle 2009; 8: 2819-2827.
35. Kosco KA, Cerignoli F, Williams S et al. SKAP55 modulates T cell antigen receptor-induced activation of the Ras-Erk-AP1 pathway by binding RasGRP1. Mol Immunol 2008; 45: 510-522.
36. Goode EL, Chenevix-Trench G, Song H et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010; 42: 874-879.
37. Li HH, Kedar V, Zhang C et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 2004; 114: 1058-1071.
38. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21: 1050-1063.
39. Chou JL, Su HY, Chen LY et al. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 2010; 90: 414-425.
40. Svensson J, Moverare-Skrtic S, Windahl S et al. Stimulation of both estrogen and androgen receptors maintains skeletal muscle mass in gonadectomized male mice but mainly via different pathways. J Mol Endocrinol 2010; 45: 45-57.